Nyumbani › Limfoma › Ohio › Cleveland
Majaribio ya kliniki ya Limfoma katika Cleveland, OH
Masomo 14 ya Limfoma yanatafuta washiriki katika vituo vya Cleveland na maeneo yake (ndani ya takriban maili 30). Fungua somo kuona nani anaweza kujiunga na jinsi ya kuwasiliana na timu ya utafiti.
Maandishi rasmi ya utafiti (Kiingereza)
Unavutia washiriki kwa utafiti hapa? Weka juu ya ukurasa huu — $99 kwa siku 30 →
T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)
InaajiriHatua 1/2
- University Hospitals Seidman Cancer Center, Cleveland
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
InaajiriHatua 1
- University Hospitals Cleveland Medical Center, Cleveland
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
InaajiriHatua 2
- Cleveland Clinic, Cleveland
A Study to Evaluate the Safety and Pharmacokinetics of Eflapegrastim in Pediatric Participants With Solid Tumors or Lymphomas and Treated With Myelosuppressive Chemotherapy
InaajiriHatua 2
- University Hospitals Cleveland Medical Center, Cleveland
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
InaajiriHatua 2
- The Cleveland Clinic Foundation, Cleveland
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
InaajiriHatua 3
- Research Site, Cleveland
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
InaajiriHatua 1/2
- Cleveland Clinic, Cleveland
A Study of REC-1245 in Participants With Unresectable, Locally Advanced, or Metastatic Cancer
InaajiriHatua 1/2
- Cleveland Clinic, Cleveland
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
InaajiriHatua 3
- Cleveland Clinical Taussig Cancer Center, Cleveland
A Study of ELA026 in Participants With Relapsed/Refractory (R/R) T/NK Cell Malignancies (TCMs)
InaajiriHatua 1
- University Hospitals Cleveland Medical Center, Cleveland
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
InaajiriHatua 1
- Cleveland Clinic, Cleveland
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
InaajiriHatua 1/2
- Cleveland Clinic, Cleveland
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
InaajiriUtafiti wa uchunguziWajitolea wenye afya wanakaribishwa
- Cleveland Clinic, Cleveland
Phase 1 Study of BAFF CAR-T Cells (LMY-920) for Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
InaajiriHatua 1
- Case Comprehensive Cancer Center, Cleveland Clinic Foundation Taussig Cancer Institute, Cleveland
Majaribio ya Limfoma katika miji mingine
- Houston, TXUtafiti 34
- Boston, MAUtafiti 33
- New York City, NYUtafiti 33
- Washington, DCUtafiti 23
- Baldwin Park, CAUtafiti 21
- Chicago, ILUtafiti 20
- Durham, NCUtafiti 17
- St. Louis, MOUtafiti 15
- Philadelphia, PAUtafiti 15
- Edison, NJUtafiti 12
- Atlanta, GAUtafiti 12
- Seattle, WAUtafiti 12
Masomo mengine katika Cleveland
- Saratani ya Mapafu Isiyo na Selu NdogoUtafiti 43
- Saratani (aina zote)Utafiti 36
- Saratani ya MatitiUtafiti 35
- Saratani ya ProstateUtafiti 34
- Kushindwa kwa MoyoUtafiti 33
- Saratani ya MetastasiUtafiti 30
- Kansari ya MayaiUtafiti 30
- Saratan ya MapafuUtafiti 26
- Kansari ya kolorektaliUtafiti 24
- Magonjwa ya Moyo na Mishipa ya DamuUtafiti 22
- Saratani ya EndometrialUtafiti 20
- Leukemia ya Myeloid ya GhaflaUtafiti 20
Kutoka ClinicalTrials.gov, data iliyopatikana 5 Okt 2026. Kila utafiti una masharti yake ya kufaa; timu ya utafiti huamua nani anaweza kujiunga.